Related Experiment Videos
[The significance of postprandial glycemia]
1Abteilung für Endokrinologie und Diabetologie Universitätsspital Zürich Rämistrasse 10 8091 Zürich.
Abstract:
Both acute and chronic hyperglycemia cause tissue lesions which ultimately lead to micro- and macrovascular diabetic complications. The newly developed insulin secretagogues and quick-acting insulin analogues are pharmacological options to reduce the amplitude of glucose fluctuations, thereby reducing acute glucose toxicity. There is hope that new pathophysiologically based therapeutic options will improve glucose control of type 2 diabetes and that physicians can be convinced to change their frequently expressed opinion that rising glucose levels represent the natural course of the disease. The Diabetes Control and Complications Trial has clearly shown that intensive insulin therapy is effective in treating complete insulin deficiency in type 1 diabetes over many years, achieving a stable HbA1c and thereby preventing diabetic complications [1].
Insights
Hyperglycemia causes diabetic complications. New therapies aim to improve glucose control and prevent these long-term health issues for both type 1 and type 2 diabetes patients.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Hyperglycemia, both acute and chronic, leads to tissue damage and diabetic complications.
- Microvascular and macrovascular complications are significant long-term consequences of uncontrolled blood glucose levels.
Purpose of the Study:
- To explore new therapeutic strategies for improving glucose control in type 2 diabetes.
- To highlight the potential of novel insulin secretagogues and rapid-acting insulin analogues in managing glucose fluctuations.
- To emphasize the importance of physician education in adopting evidence-based treatment approaches for diabetes.
Main Methods:
- Review of pharmacological options including insulin secretagogues and insulin analogues.
- Discussion of findings from landmark trials like the Diabetes Control and Complications Trial (DCCT).
- Analysis of the impact of glucose fluctuations on acute glucose toxicity.
Main Results:
- Pharmacological interventions can reduce glucose variability and acute glucose toxicity.
- Intensive insulin therapy demonstrated effectiveness in preventing complications in type 1 diabetes over the long term.
- Evidence suggests improved glucose control is achievable and can prevent diabetic complications.
Conclusions:
- New therapeutic avenues offer promise for better diabetes management.
- Reducing glucose fluctuations is key to mitigating acute glucose toxicity.
- Challenging the perception of rising glucose as inevitable is crucial for effective diabetes care.